Cantor Fitzgerald Weighs in on Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Kura Oncology in a report issued on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings of ($2.94) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Several other equities analysts have also commented on the stock. JMP Securities reiterated a "market outperform" rating and set a $28.00 price objective on shares of Kura Oncology in a research report on Thursday, February 6th. Jefferies Financial Group lowered their price target on shares of Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a report on Thursday, November 21st. HC Wainwright restated a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. StockNews.com raised Kura Oncology from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Wedbush reissued an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Three investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Remove Ads

Kura Oncology Price Performance

Shares of NASDAQ KURA traded down $0.17 during midday trading on Thursday, reaching $7.53. 1,291,397 shares of the stock traded hands, compared to its average volume of 1,591,525. The company's 50 day moving average is $8.00 and its 200 day moving average is $13.29. Kura Oncology has a one year low of $6.98 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market capitalization of $608.09 million, a PE ratio of -3.19 and a beta of 0.85.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. The trade was a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the firm's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock valued at $92,307 in the last quarter. 5.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Kura Oncology by 104.5% in the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after buying an additional 84,563 shares during the period. SG Americas Securities LLC purchased a new stake in Kura Oncology in the fourth quarter worth about $436,000. Moody Aldrich Partners LLC grew its holdings in Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after acquiring an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. increased its position in Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock valued at $430,000 after purchasing an additional 2,076 shares during the period. Finally, Jennison Associates LLC bought a new stake in shares of Kura Oncology in the 4th quarter valued at about $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.